O-SEMA-FastControl de Azúcar en Sangre con Semaglutida Oral en Pacientes con Diabetes Tipo 2 Durante el Ayuno de Ramadán

This study focuses on individuals with type 2 diabetes who plan to fast during Ramadan and are using oral Semaglutide, a once-daily medication. The main goal is to understand how this medication affects their blood sugar control during this period. The study is important as it aims to provide insights into the safety and effectiveness of oral Semaglutide for diabetic patients who fast, potentially improving their care and management during Ramadan. Participants in this study will take oral Semaglutide as directed by their study doctor. The study lasts about 5 months, during which participants will keep a diary about their medication usage. They will record how and when they take their oral Semaglutide tablets. The primary outcome measured is the change in glycated haemoglobin (HbA1c), which gives an indication of average blood sugar levels over a period of time. This will help evaluate the effectiveness of oral Semaglutide in maintaining blood sugar control during fasting.